ホーム › 膠芽腫 › マサチューセッツ州 › Boston
Boston、MAにおける膠芽腫の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、膠芽腫に関する28件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
被験者募集中第2/3相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Dana Farber Cancer Institute., Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Tufts Medical Center, Boston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
Targeted Pediatric High-Grade Glioma Therapy
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
被験者募集中
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
被験者募集中第2相
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
被験者募集中第1相
- Massachusetts General Hospital Cancer Center, Boston
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
被験者募集中早期第1相健康なボランティア歓迎
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
G-CSF After Chemo-radiation in Patients With Glioblastoma
被験者募集中第2相
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
CUE-102 in Recurrent Glioblastoma
被験者募集中第1相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
被験者募集中第2相
- Brigham and Women's Hospital, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
被験者募集中早期第1相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Implantable Microdevice In Primary Brain Tumors
被験者募集中早期第1相
- Brigham and Women's Hospital, Boston
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
被験者募集中観察研究
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
被験者募集中観察研究
- Massachusetts General Hospital, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
被験者募集中観察研究
- Massachusetts General Hospital, Boston
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
被験者募集中観察研究
- Massachusetts General Hospital, Boston
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
被験者募集中観察研究
- Massachusetts General Hospital, Boston
他の都市における膠芽腫の試験
- New York City, NY30件の研究
- Houston, TX26件の研究
- Los Angeles, CA24件の研究
- Durham, NC20件の研究
- San Francisco, CA17件の研究
- Chicago, IL15件の研究
- Washington, DC15件の研究
- Columbus, OH14件の研究
- Miami, FL14件の研究
- Rochester, MN13件の研究
- Jacksonville, FL13件の研究
- Aurora, CO12件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。